Dr. Bal is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
619 19th St S
Birmingham, AL 35249Phone+1 205-934-4011
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2019 - 2019
University of Cincinnati Medical Center/College of MedicineFellowship, Hematology and Medical Oncology, 2015 - 2018
Kettering Health Network/Kettering Medical CenterResidency, Internal Medicine, 2012 - 2015
Bharti Vidyapeeth Medical CollegeClass of 2012
Certifications & Licensure
AL State Medical License 2019 - 2024
OH State Medical License 2012 - 2018- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
Clinical Trials
- Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE) Start of enrollment: 2021 Sep 22
Publications & Presentations
PubMed
- 5 citationsClinical implications of measurable residual disease assessment in multiple myeloma in the era of quadruplet therapy.Susan Bal, Timothy M Schmidt, Luciano J Costa, Natalie S Callander
Leukemia & Lymphoma. 2022-12-01 - 5 citationsDaratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk.Natalie S Callander, Rebecca Silbermann, Jonathan L Kaufman, Kelly N Godby, Jacob Laubach
Blood Cancer Journal. 2024-04-22 - 64 citationsEvaluation of Daratumumab for the Treatment of Multiple Myeloma in Patients With High-risk Cytogenetic Factors: A Systematic Review and Meta-analysis.Smith Giri, Alyssa Grimshaw, Susan Bal, Kelly N. Godby, Prakash Kharel
JAMA Oncology. 2020-11-01
Journal Articles
- Caution with Routine Use of Daratumumab for Newly Diagnosed High-Risk Multiple Myeloma—ReplySusan Bal, MD, JAMA Oncology
- Evaluation of Daratumumab for the Treatment of Multiple Myeloma in Patients with High-Risk Cytogenetic FactorsSusan Bal, Benjamin Djulbegovic, Saad Z Usmani, JAMA Oncology
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
